| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Icenticaftor targets the CFTR channel. It acts as a potentiator, enhancing the function of the CFTR chloride channel. It has the ability to restore CFTR function in both wild-type and particular CFTR genotypes. The compound shows EC50s of 79 nM and 497 nM for F508del and G551D CFTR, respectively.
|
|---|---|
| ln Vitro |
Icenticaftor (QBW251) is a small molecule CFTR enhancer that may be taken orally and is bioavailable. It has the ability to restore CFTR function in both wild-type and particular CFTR genotypes [2].
In vitro, Icenticaftor potentiates the CFTR channel with EC50s of 79 nM for F508del CFTR and 497 nM for G551D CFTR. It exhibits bioactivities related to potency in enhancing chloride transport through CFTR in various cell models. |
| ln Vivo |
The pharmacokinetic profile of Icenticaftor was developed in Sprague-Dawley rats. After an oral dosage of 3 mg/kg, the oral bioavailability is 90% and the AUClast is 20 635 nmol/L·h[1].
In vivo activity data for Icenticaftor are not extensively detailed in the available sources. The compound is an orally active CFTR potentiator. It has shown clinical efficacy in cystic fibrosis and chronic obstructive pulmonary disease. |
| Enzyme Assay |
The in vitro assay for Icenticaftor involves measuring CFTR-mediated chloride transport in cells expressing CFTR. Cells are treated with the compound, and chloride flux is measured using fluorescent indicators or electrophysiological techniques. EC50 values are determined from dose-response curves.
|
| Cell Assay |
Cellular assays for Icenticaftor are performed using cell models expressing wild-type or mutant CFTR. Cells are treated with the compound at varying concentrations. CFTR function is assessed by measuring chloride transport.
|
| Animal Protocol |
In vivo animal studies for Icenticaftor are not detailed in the available sources. The compound is an orally active CFTR potentiator. Specific animal models and dosing regimens have not been described.
|
| ADME/Pharmacokinetics |
Icenticaftor is an orally bioavailable compound. It has a molecular weight of 361.24 g/mol. The compound has shown clinical efficacy in cystic fibrosis and chronic obstructive pulmonary disease. Specific PK parameters are not detailed in the available sources.
|
| Toxicity/Toxicokinetics |
Toxicity data for Icenticaftor are not reported in the available sources. As a research compound, it is not intended for therapeutic use. Specific toxicological profiles have not been characterized.
|
| References |
|
| Additional Infomation |
Icenticaftor is a research compound for studying CFTR function in cystic fibrosis and chronic obstructive pulmonary disease. It is an orally active CFTR channel potentiator. The compound is available from commercial suppliers for research use only. A reference describing its discovery is available (J Med Chem).
|
| Molecular Formula |
C12H13F6N3O3
|
|---|---|
| Molecular Weight |
361.240343809128
|
| Exact Mass |
361.09
|
| Elemental Analysis |
C, 39.90; H, 3.63; F, 31.55; N, 11.63; O, 13.29
|
| CAS # |
1334546-77-8
|
| Related CAS # |
1334546-77-8;
|
| PubChem CID |
58442344
|
| Appearance |
White to yellow solid powder
|
| LogP |
2.2
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
458
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@](CNC(=O)C1=C(C=C(C(=N1)OC)C(F)(F)F)N)(C(F)(F)F)O
|
| InChi Key |
USHQRIKZLHNPQR-JTQLQIEISA-N
|
| InChi Code |
InChI=1S/C12H13F6N3O3/c1-10(23,12(16,17)18)4-20-8(22)7-6(19)3-5(11(13,14)15)9(21-7)24-2/h3,23H,4,19H2,1-2H3,(H,20,22)/t10-/m0/s1
|
| Chemical Name |
3-amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)pyridine-2-carboxamide
|
| Synonyms |
Icenticaftor; QBW251; QBW 251; QBW-251;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~150 mg/mL (~415.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 4.25 mg/mL (11.77 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 42.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 4.25 mg/mL (11.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 42.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 4.25 mg/mL (11.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7682 mL | 13.8412 mL | 27.6824 mL | |
| 5 mM | 0.5536 mL | 2.7682 mL | 5.5365 mL | |
| 10 mM | 0.2768 mL | 1.3841 mL | 2.7682 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
